Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

60 Degrees Pharmaceuticals (SXTP) EBITDA Margin (2022 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed EBITDA Margin for 4 consecutive years, with 531.42% as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA Margin rose 106406.0% to 531.42% in Q3 2025 year-over-year; TTM through Sep 2025 was 833.88%, a 77207.0% increase, with the full-year FY2024 number at 1309.43%, up 17020.0% from a year prior.
  • EBITDA Margin was 531.42% for Q3 2025 at 60 Degrees Pharmaceuticals, up from 1590.01% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 8171.61% in Q3 2023 to a low of 15134.08% in Q1 2023.
  • A 4-year average of 1479.69% and a median of 1153.43% in 2025 define the central range for EBITDA Margin.
  • Biggest YoY gain for EBITDA Margin was 1553775bps in 2024; the steepest drop was -976710bps in 2024.
  • 60 Degrees Pharmaceuticals' EBITDA Margin stood at 4446.47% in 2022, then tumbled by -136bps to 1585.0% in 2023, then surged by 46bps to 849.49% in 2024, then soared by 37bps to 531.42% in 2025.
  • Per Business Quant, the three most recent readings for SXTP's EBITDA Margin are 531.42% (Q3 2025), 1590.01% (Q2 2025), and 1153.43% (Q1 2025).